Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women

American Journal of Obstetrics and Gynecology

Volumn 187, Issue 3, 2002, Pages 569-574

  Bauters, Tiene G M ^a   Dhont, Marc A ^b   Temmerman, Marleen I L ^b   Nelis, Hans J ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Antifungal; Susceptibility; Vulvovaginal candidiasis

Indexed keywords

FLUCONAZOLE; ORAL CONTRACEPTIVE AGENT; POTASSIUM HYDROXIDE;

ARTICLE; CANDIDA ALBICANS; DRUG SENSITIVITY; ESTROGEN BLOOD LEVEL; FEMALE; FUNGUS ISOLATION; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT DEPARTMENT; PREVALENCE; PRIORITY JOURNAL; VAGINA CANDIDIASIS;

EID: 0036739333     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2002.125897     Document Type: Article

References (25)

1. Sobel JD. Genital candidiasis. In: Bodey GP, editor. Candidiasis: pathogenesis, diagnosis and treatment. New York: Raven Press; 1993. p. 225-47.
2. Spinillo A, Capuzzo E, Egbe T, Baltaro F, Nicola S, Piazzi G. Torulopsis glabrata vaginitis. Obstet Gynecol 1995;85:993-8.
3. Sobel JD, Faro S, Force R, Foxman B, Ledger W, Nyirjesy P, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998;2:203-11.
4. Bauters TGM, Peleman R, Moerman M, Vermeersch H, De Looze D, Noens L, et al. Membrane filtration test for rapid presumptive differentiation of four Candida species. J Clin Microbiol 1999;37:1498-502.
5. Houang ETS, Chu KC, Koehler AP, Cheng AFB. Use of CHRO-Magar Candida for genital specimens in the diagnostic laboratory. J Clin Pathol 1997;50:563-5.
6. National Committee for Clinical Laboratory Standards (NCCLS). Reference method for broth dilution antifungal susceptibility testing of yeasts: standard M27A. Villanova (Pa): National Committee for Clinical Laboratory Standards; 1995.
7. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, et al. Development of interpretative breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997;24:235-47.
8. Spinillo A, Capuzzo E, Acciano S, De Santolo A, Zara F. Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis. Am J Obstet Gynecol 1998;1:14-7.
9. de Oliveira JM, Cruz AS, Fonseca AF, Vaz CP, Rodrigues A, Aurea F, et al. Prevalence of Candida albicans in vaginal fluid of asymptomatic Portuguese women. J Reprod Med 1993;38:41-2.
10. Abu-Elteen KH, Abdul Malek AMM, Abdul Wahid NAA. Prevalence and susceptibility of vaginal yeast isolates in Jordan. Mycoses 1997;40:179-85.
11. Goldacre MJ, Watt B, Loudon N, Milne LJ, Loudon JD, Vessey MP. Vaginal microbial flora in normal young women. Br Med J 1979;1:1450-3.
12. Geiger AM, Foxman B. Risk factors in vulvovaginal candidiasis: a case-control study among college students. Epidemiology 1996;7:182-7.
13. Spinillo A, Capuzzo F, Nicola S, Baltaro F, Ferrari A, Monaco A. The impact of oral contraception on vulvovaginal candidiasis. Contraception 1995;51:293-7.
14. Kent HL. Epidemiology of vaginitis. Am J Obstet Gynecol 1991;165:1168-76.
15. Cotch MF, Hillier SL, Gibbs RS, Eschenbach DA. Epidemiology and outcomes associated with moderate to heavy Candida colonization during pregnancy. Am J Obstet Gynecol 1998;179:374-80.
16. Perera J, Clayton Y. Incidence, species distribution and antifungal sensitivity pattern of vaginal yeasts in Sri Lankan women. Mycoses 1994;37:357-60.
17. Spinillo A, Bernuzzi AM, Cevini C, Gulminetti R, Luzi S, De Santalo A. The relationship of bacterial vaginosis, Candida and Trichomonas infections to symptomatic vaginitis in postmenopausal women attending a vaginitis clinic. Maturitas 1997;27:253-60.
18. Hillier S, Lau RJ. Vaginal microflora in postmenopausal women who have not received estrogen replacement therapy. Clin Infect Dis 1997;25 (suppl):S123-6.
19. Davidson F, Oates JK. The pill does not cause "thrush". Br J Obstet Gynecol 1985;92:1265-6.
20. Parewijck W, Claeys G, Thiery M, Van Kets H. Candidiasis in women fitted with an intrauterine contraceptive device. Br J Obstet Gynecol 1988;95:408-10.
21. Voss A, Wallrauch-Schwarz C, Milatoviv CD, Braveny I, Johannigmann J, Hanke-Baier P. Quantitative study of vaginal flora during the menstrual cycle. Geburtshilfe Frauenheilkd 1993; 53:543-6.
22. Fidel P, Cutright J, Steele C. Effects of reproductive hormones on experimental vaginal candidiasis. Infect Immun 2000;651-7.
23. Cuenca-Estrella M, Rodriguez-Tudela JL. Present status of the detection of antifungal resistance: the perspective from both sides of the ocean. Clin Microbiol Infect 2001;7(2 Suppl):46-53.
24. Rodriguez-Tudela JL, Cuenca-Estrella M, Diaz-Guerra T, Mellado E. Standardization of antifungal susceptibility variables for a semiautomated methodology. J Clin Microbiol 2001; 39:2513-7.
25. Warnock DW, Johnson EM, Rogers TR. Multi-centre evaluation of the E-test method for antifungal drug susceptibility testing of Candida spp and Cryptococcus neoformans: BSAC working party on antifungal chemotherapy. J Antimicrob Agents 1998;42:321-31.